Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
Contraception
Depot medroxyprogesterone acetate (DMPA)
Injectable
Self-administration
Self-injection
Subcutaneous DMPA
Journal
Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
16
03
2022
revised:
22
03
2022
accepted:
23
03
2022
pubmed:
5
4
2022
medline:
20
7
2022
entrez:
4
4
2022
Statut:
ppublish
Résumé
Depot medroxyprogesterone acetate (DMPA) is a highly-effective, injectable contraceptive method that requires injections every 12 to 15 weeks. The need for return visits to a healthcare provider may present barriers to access, use, and continuation of DMPA. Studies demonstrate that self-administration of subcutaneous DMPA (DMPA-SC) outside clinical settings is safe, effective, feasible, acceptable, and can improve continuation. Based on existing evidence and potential to improve contraceptive access and autonomy, the Society of Family Planning recommends that DMPA-SC self-administration be made widely available as an additional option for patients. Provider-administered DMPA must also remain available to meet patients' individual needs and preferences.
Identifiants
pubmed: 35378085
pii: S0010-7824(22)00083-X
doi: 10.1016/j.contraception.2022.03.023
pii:
doi:
Substances chimiques
Contraceptive Agents, Female
0
Medroxyprogesterone Acetate
C2QI4IOI2G
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-13Informations de copyright
Copyright © 2022. Published by Elsevier Inc.